[{"id":"7246a629-768b-4557-b16c-b951baaa4ed1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03742258","created_at":"2021-01-18T18:19:49.340Z","updated_at":"2025-02-25T15:34:14.094Z","phase":"Phase 1","brief_title":"Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT03742258","lead_sponsor":"Northwestern University","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • mivavotinib (CB-659) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 03/12/2021","primary_completion_date":" 03/12/2021","study_txt":" Completion: 12/19/2028","study_completion_date":" 12/19/2028","last_update_posted":"2025-02-11"},{"id":"961c39f5-982d-49c6-8dfa-778598f18be0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06093841","created_at":"2023-10-23T20:14:00.026Z","updated_at":"2025-02-25T15:28:23.588Z","phase":"Phase 2","brief_title":"Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL","source_id_and_acronym":"NCT06093841","lead_sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","biomarkers":" BCL2","pipe":" | ","alterations":" MYC rearrangement • BCL2 rearrangement","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Carteyva (relmacabtagene autoleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 11/03/2023","start_date":" 11/03/2023","primary_txt":" Primary completion: 01/21/2024","primary_completion_date":" 01/21/2024","study_txt":" Completion: 11/04/2029","study_completion_date":" 11/04/2029","last_update_posted":"2025-02-11"},{"id":"e7cf2c99-6cfe-4015-9ca9-b9a242d379a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04739813","created_at":"2021-02-05T13:56:26.764Z","updated_at":"2025-02-25T16:38:14.078Z","phase":"Phase 1","brief_title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT04739813","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • UGT1A1","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation","tags":["BCL2 • BCL6 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/09/2021","start_date":" 07/09/2021","primary_txt":" Primary completion: 10/29/2025","primary_completion_date":" 10/29/2025","study_txt":" Completion: 10/29/2030","study_completion_date":" 10/29/2030","last_update_posted":"2025-02-06"},{"id":"9cceceb2-4e58-41ef-ba8e-6eddd7740571","acronym":"","url":"https://clinicaltrials.gov/study/NCT05371054","created_at":"2022-05-12T15:56:31.055Z","updated_at":"2024-07-02T16:34:37.584Z","phase":"Phase 1/2","brief_title":"Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies","source_id_and_acronym":"NCT05371054","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • BCL2","pipe":" | ","alterations":" MYC rearrangement","tags":["ALK • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • prednisone • enitociclib (VIP152)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 04/05/2023","start_date":" 04/05/2023","primary_txt":" Primary completion: 03/10/2025","primary_completion_date":" 03/10/2025","study_txt":" Completion: 03/10/2025","study_completion_date":" 03/10/2025","last_update_posted":"2024-06-06"},{"id":"e6bd139e-7d5b-486d-888f-481618f10fed","acronym":"LONCA","url":"https://clinicaltrials.gov/study/NCT05270057","created_at":"2022-03-08T16:52:28.981Z","updated_at":"2024-07-02T16:34:59.173Z","phase":"Phase 1","brief_title":"Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies","source_id_and_acronym":"NCT05270057 - LONCA","lead_sponsor":"Medical College of Wisconsin","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 01/26/2023","start_date":" 01/26/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-06-04"},{"id":"4095393f-1afe-4397-9aa9-0d3e7de48147","acronym":"","url":"https://clinicaltrials.gov/study/NCT06045247","created_at":"2023-09-21T15:10:50.286Z","updated_at":"2024-07-02T16:35:00.377Z","phase":"Phase 2","brief_title":"Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT06045247","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":" | ","alterations":" MYC rearrangement • BCL2 rearrangement","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • vincristine • prednisone • Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/05/2024","start_date":" 01/05/2024","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 07/31/2030","study_completion_date":" 07/31/2030","last_update_posted":"2024-05-29"},{"id":"825a0e35-0b45-4a5a-bf8e-33ed379203ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05869279","created_at":"2023-05-22T16:05:43.593Z","updated_at":"2024-07-02T16:35:05.947Z","phase":"Phase 1/2","brief_title":"Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT05869279","lead_sponsor":"Fondazione Matilde Tettamanti Menotti De Marchi Onlus","biomarkers":" BCL2","pipe":" | ","alterations":" MYC rearrangement • BCL2 rearrangement","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CARCIK-CD19"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-05-03"},{"id":"5d576388-a550-4b35-b698-5134873cd7dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03793140","created_at":"2021-01-18T18:45:13.009Z","updated_at":"2024-07-02T16:35:08.385Z","phase":"Phase 2","brief_title":"A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations","source_id_and_acronym":"NCT03793140","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bylantra (devimistat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/31/2018","start_date":" 12/31/2018","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-22"},{"id":"6a54e9ca-ab14-4985-b527-5f222345e52f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04307576","created_at":"2021-01-18T20:53:16.021Z","updated_at":"2024-07-02T16:35:14.109Z","phase":"Phase 3","brief_title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","source_id_and_acronym":"NCT04307576","lead_sponsor":"Mats Heyman","biomarkers":" MYC • BCL2 • KMT2A","pipe":" | ","alterations":" MYC rearrangement + BCL2 rearrangement • MLL rearrangement • MYC rearrangement • MYC translocation • BCL2 rearrangement","tags":["MYC • BCL2 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement + BCL2 rearrangement • MLL rearrangement • MYC rearrangement • MYC translocation • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • doxorubicin hydrochloride • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • thioguanine"],"overall_status":"Recruiting","enrollment":" Enrollment 6430","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2032","study_completion_date":" 06/30/2032","last_update_posted":"2024-03-19"},{"id":"54641fd7-3e2b-47aa-b1a9-559d178b47d9","acronym":"HOVON-152","url":"https://clinicaltrials.gov/study/NCT03620578","created_at":"2021-01-18T17:47:26.626Z","updated_at":"2024-07-02T16:35:19.406Z","phase":"Phase 2","brief_title":"DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL","source_id_and_acronym":"NCT03620578 - HOVON-152","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" PD-L1 • BCL2 • BCL6","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["PD-L1 • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 01/30/2024","primary_completion_date":" 01/30/2024","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-02-14"},{"id":"14041a82-573a-4b07-85ab-c7be6f6788c2","acronym":"POLAR BEAR","url":"https://clinicaltrials.gov/study/NCT04332822","created_at":"2021-01-18T20:58:50.332Z","updated_at":"2024-07-02T16:35:19.585Z","phase":"Phase 3","brief_title":"A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma","source_id_and_acronym":"NCT04332822 - POLAR BEAR","lead_sponsor":"Nordic Lymphoma Group","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" MYC rearrangement + BCL2 rearrangement • MYC rearrangement • BCL2 rearrangement","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement + BCL2 rearrangement • MYC rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 08/19/2020","start_date":" 08/19/2020","primary_txt":" Primary completion: 12/28/2025","primary_completion_date":" 12/28/2025","study_txt":" Completion: 12/28/2028","study_completion_date":" 12/28/2028","last_update_posted":"2024-02-13"},{"id":"2ec47635-b74f-44b7-8369-7b60baf401db","acronym":"","url":"https://clinicaltrials.gov/study/NCT01193842","created_at":"2021-01-18T04:46:39.937Z","updated_at":"2024-07-02T16:35:28.434Z","phase":"Phase 1/2","brief_title":"Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas","source_id_and_acronym":"NCT01193842","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement • CD20 negative","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Zolinza (vorinostat) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 10/06/2010","start_date":" 10/06/2010","primary_txt":" Primary completion: 11/12/2016","primary_completion_date":" 11/12/2016","study_txt":" Completion: 05/19/2022","study_completion_date":" 05/19/2022","last_update_posted":"2023-11-21"},{"id":"26065744-c262-4f87-91b1-e6294c2cfbc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04323956","created_at":"2021-01-18T20:56:54.236Z","updated_at":"2024-07-02T16:35:31.265Z","phase":"Phase 1","brief_title":"Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04323956","lead_sponsor":"Mayo Clinic","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • parsaclisib (INCB50465) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2023-10-30"},{"id":"ddab7878-bbd6-408a-871f-fa049fe36f03","acronym":"CARTHEDRALL","url":"https://clinicaltrials.gov/study/NCT06101381","created_at":"2023-10-26T15:14:01.501Z","updated_at":"2024-07-02T16:35:31.635Z","phase":"Phase 1/2","brief_title":"CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma","source_id_and_acronym":"NCT06101381 - CARTHEDRALL","lead_sponsor":"University of Sao Paulo","biomarkers":" BCL2","pipe":" | ","alterations":" CD19 positive • MYC rearrangement • CD19 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • MYC rearrangement • CD19 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2023-10-26"},{"id":"642bd716-2adc-4e1e-9e83-d1fcc5dbe602","acronym":"","url":"https://clinicaltrials.gov/study/NCT02417285","created_at":"2021-03-25T18:07:07.062Z","updated_at":"2024-07-02T16:35:32.080Z","phase":"Phase 1b","brief_title":"A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.","source_id_and_acronym":"NCT02417285","lead_sponsor":"Celgene","biomarkers":" MYC • BCL2 • CD20","pipe":" | ","alterations":" CD20 positive • MYC overexpression • MYC rearrangement","tags":["MYC • BCL2 • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • MYC overexpression • MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • avadomide (CC-122)"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 05/22/2015","start_date":" 05/22/2015","primary_txt":" Primary completion: 05/27/2019","primary_completion_date":" 05/27/2019","study_txt":" Completion: 09/28/2023","study_completion_date":" 09/28/2023","last_update_posted":"2023-10-23"},{"id":"7a85cb36-6636-4b7a-af50-42acb1ec66e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04231448","created_at":"2021-01-18T20:35:06.017Z","updated_at":"2024-07-02T16:35:38.070Z","phase":"Phase 3","brief_title":"Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL","source_id_and_acronym":"NCT04231448","lead_sponsor":"Chipscreen Biosciences, Ltd.","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" CD20 positive • MYC rearrangement","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 423","initiation":"Initiation: 05/21/2020","start_date":" 05/21/2020","primary_txt":" Primary completion: 07/05/2023","primary_completion_date":" 07/05/2023","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-09-06"},{"id":"8d92e145-1e5f-4e56-b472-cedf7cfc6b38","acronym":"COALITION","url":"https://clinicaltrials.gov/study/NCT04914741","created_at":"2021-06-07T16:53:40.225Z","updated_at":"2024-07-02T16:35:39.206Z","phase":"Phase 1/2","brief_title":"A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT04914741 - COALITION","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/29/2021","start_date":" 06/29/2021","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-08-23"},{"id":"a4ec1eb0-717c-4885-999a-6e9126e9bc1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05498636","created_at":"2022-08-19T18:11:07.980Z","updated_at":"2024-07-02T16:36:05.112Z","phase":"Phase 1/2","brief_title":"SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression","source_id_and_acronym":"NCT05498636","lead_sponsor":"The Affiliated Hospital of Qingdao University","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" MYC overexpression • MYC expression • MYC rearrangement • BCL2 rearrangement","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • MYC rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • etoposide IV • Xpovio (selinexor) • prednisone"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-08-19"},{"id":"af2ddd01-c302-4d1b-9b6a-8665f4437f5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02481310","created_at":"2021-01-18T11:56:55.356Z","updated_at":"2025-02-25T14:57:14.569Z","phase":"Phase 1/2","brief_title":"Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02481310","lead_sponsor":"Northwestern University","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" MYC rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • Ninlaro (ixazomib) • vincristine • prednisone • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 10/28/2015","start_date":" 10/28/2015","primary_txt":" Primary completion: 09/26/2020","primary_completion_date":" 09/26/2020","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-02-21"}]